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Abstract
Background & Aims—Regular use of aspirin and other non-steroidal anti-inflammatory drugs
(NSAID) has been reported to reduce risks for esophageal adenocarcinoma (EAC) and
esophagogastric junctional adenocarcinoma (EGJA). However, individual studies have been too
small to accurately assess the effects of medication type, frequency, or duration of use. We
performed a pooled analysis to investigate these associations.
Methods—We performed a pooled analysis of 6 population-based studies within the Barrett's
and Esophageal Adenocarcinoma Consortium to evaluate the association between NSAID use and
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the risk of EAC and EGJA, using uniform exposure definitions. We collected information from 6
studies (5 case-control and 1 cohort), with a total of 1226 EAC and 1140 EGJA cases, on aspirin
and/or NSAID use. Study-specific odds ratios (ORs) and 95% confidence intervals (CIs) were
estimated using multivariate adjusted logistic regression models and then pooled using a random
effects meta-analysis model.
Results—Compared to non-users, individuals who have used NSAIDs had a statistically
significant, reduced risk of EAC (OR=0.68; 95% CI, 0.56–0.82); they also appeared to have a
reduced risk of EGJA (OR=0.84; 95% CI, 0.68–1.03). Similar reductions in risk were observed
among individuals who took aspirin or non-aspirin NSAIDs. The highest levels of frequency
(≥daily) and duration (≥10 years) of NSAID use were associated with an approximately 40%
reduction in risk for EAC: OR=0.56 (95% CI, 0.43–0.73; P-trend, <.001) and OR=0.63 (95% CI,
0.45–0.90; P-trend, 0.04), respectively.
Conclusions—Although reverse causation could, in part, explain the inverse association
observed between NSAID use and EAC risk, pooled analysis indicates a role for NSAIDs in
prevention of adenocarcinomas of the esophagus and esophagogastric junction.
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Introduction
The incidence of esophageal adenocarcinoma (EAC) has increased considerably in many
Western countries over the past three decades 1, 2. The disease continues to have a very low
survival rate 3. Esophagogastric junctional adenocarcinomas (EGJA) are a heterogeneous
group of adenocarcinomas which reside within the gastric cardia and/or the
gastroesophageal junction. Similar to EAC, upward trends of EGJA have been reported in
Western countries in recent years4, 5.
Inflammation, caused by factors such as gastroesophageal reflux, is believed to cause EGJA
and EAC, suggesting a plausible preventative role for anti-inflammatory agents. A primary
preventive mechanism for non-steroidal anti-inflammatory drugs (NSAIDs) is thought to be
the inhibition of cyclooxygenase-2 (COX-2) production, an enzyme that is an important
mediator of inflammation 6, 7. Elevated COX-2 expression has been observed in Barrett's
esophagus, a precursor lesion of EAC, with expression levels noted to increase with disease
progression to EAC 8, 9. Experimental studies have also shown that treatment with COX-2
inhibitors can inhibit the growth in vitro of Barrett's esophagus cells, an effect potentially
mediated by suppression of basic fibroblast growth factor 10-12. Higher levels of COX-2
expression also have been detected in gastric carcinomas 13. Although several studies have
observed that COX-2 inhibitors slow the growth of gastric tumor cells and induce apoptosis,
they have also suggested that this may be mediated through pathways other than suppressing
COX-214, 15.
Frequent use of NSAIDs has been associated with a reduced risk of gastrointestinal cancers
in many epidemiologic studies 16, 17. Studies conducted thus far on NSAID use have
focused mainly on colorectal cancer, with a smaller but growing number of studies
investigating NSAID use in relation to esophageal and gastric cancers. The majority of these
studies support an inverse association between NSAID use and risk of EAC and EGJA 18-26.
Previous reviews have largely limited their evaluations of NSAID use and risk of EAC and
EGJA to assessments of ever- use 27-31. It is not known whether specific characteristics of
NSAID use, such as frequency or duration of use, are important in reducing the risks of
specific subtypes of these cancers.
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The Barrett's and Esophageal Adenocarcinoma Consortium (BEACON) was established in
2005 in part to assemble a large sample size of well-characterized patients with esophageal
adenocarcinoma or Barrett's esophagus and representative controls, which would allow us to
better define risk factors of Barrett's esophagus and adenocarcinomas of the esophagus and
gastroesophageal junction 32. We performed a pooled analysis of studies within the
BEACON consortium, after harmonization of variables using individual-level data, to




Among the twelve BEACON studies, we identified six with sufficient information on aspirin
and non-aspirin NSAID use to contribute to the pooled analyses of EAC (Table 1). Five
studies were population-based case-control studies: the Australian Study of Esophageal
Cancer 33, the Nova Scotia Barrett Esophagus Study 34, the United States Multi-center
Study 24, the Factors Influencing the Barrett's Adenocarcinoma Relationship Study 20, and
the Los Angeles County Multi-Ethnic Study 35; and one was a cohort study: the National
Institutes of Health-AARP (NIH-AARP) Diet and Health Study 29. The NIH-AARP cohort
study provided data on all eligible cases and a random subset of controls (4:1) from among
cohort members with follow-up through 2003. Data acquired and data pooling for each
study was approved by the institutional review board or research ethics committee of the
institute sponsoring the study.
Since cancers that arise from the cardia of the stomach and the gastroesophageal junction
present distinct features in comparison with cancers from the distal portion of the stomach,
we have chosen to define adenocarcinomas of the gastric cardia and gastroesophageal
junction as EGJA in this analysis. Our analysis was restricted to Caucasians as there were
few non-Caucasian case subjects (n=75 EAC, n=96 EGJA) among the studies with available
information on NSAIDs. The six studies contributed data on a total of 1226 EAC cases,
1140 EGJA cases, and 5314 controls.
Exposure variables
For this analysis, the main exposures of interest were the use of aspirin, non-aspirin
NSAIDs, and all NSAIDs (aspirin and non-aspirin NSAIDs combined). The questionnaires
from each study were reviewed and all questions that assessed the use of individual NSAIDs
-- aspirin and other non-aspirin NSAIDs -- and overall NSAIDs were extracted. Questions
from each study were asked in various formats (both open-ended and predefined responses)
and ranged from a simple yes/no question to more detailed questions regarding frequency
and duration of use of specific drugs (Appendix A). Data were then formatted to create a
uniform exposure suitable for pooling and estimating effects of each exposure. Category
cutpoints for both frequency and duration were chosen based on the literature and after
evaluating how each study categorized these variables in their original data. Each exposure
was evaluated and categorized, as follows: ever (subdivided into current and former, when
possible) versus non-use, frequency of use (non-use, 0.1 to <1/week, ≥1 to <7/week, ≥7/
week), and duration of use (non-use, 0.1 to <5 years, ≥5 to <10 years, ≥10 years).
Participants categorized as having “Non-use” were those who indicated “no” or “never” to
any questions regarding their NSAID use (Appendix A). “Current use” was defined as
individuals who continued to take the drugs as of the interview date, or indicated that the age
or calendar year that they stopped taking the drugs was within a year of the interview date. If
the number of cases in a category was too small in the pooled dataset, the category was
collapsed together with a neighboring category. Determination of overall NSAID frequency
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and duration was calculated by combining information from both aspirin and non-aspirin
NSAID use when available. If the questionnaire did not differentiate between the two types
of NSAIDS and only asked questions on overall NSAID use, these values were then used for
estimates of overall NSAID frequency and duration. For duration of overall NSAID use, we
summed years of aspirin use and non-aspirin NSAID use. For frequency of overall NSAID
use, we calculated a combined frequency that was weighted by the duration of aspirin use
and non-aspirin NSAID use (NSAIDfreq = [(Asprinfreq*Asprinduration) + (Non-aspirin
NSAIDfreq*Non-aspirin NSAIDduration)] / [Aspirinduration+Non-aspirin NSAIDduration]). If
information on frequency was recorded in categories, we assigned the median of each
previously defined category as the value for that specific category. Actual amount or dosage
for NSAID use was not available from any of the study questionnaires.
A major advantage of having access to the individual patient data from each study is that
similar study-specific analytic models can be built, thus increasing the validity of their
combination using a meta-analytic model. Additional variables that were acquired from each
study and considered as covariates for this analysis included: age, sex, body mass index
(BMI: kg/m2), gastroesophageal reflux status (ever versus no), education, smoking exposure
(pack-years), alcohol intake (drinks per day) and study center. Age was defined as age at
diagnosis for cases, age at interview for controls from case-control studies, and age at
baseline for participants from cohort studies. BMI was calculated by dividing weight (kg) by
the square of height (m). Gastroesophageal reflux status was missing in two studies 29, 34. A
study-specific education variable was used in analyses as a different method of
categorization was employed in each study. Smoking exposure was characterized by pack-
years of tobacco exposure (number of cigarettes smoked per day x number of years smoked /
20) and has been previously described 32. Alcohol intake was measured as the average
frequency of alcohol consumption 36.
Statistical Analysis
The analyses were conducted in two stages. We first used unconditional logistic regression
to calculate study-specific estimates of odds ratios (OR) and 95% confidence intervals (95%
CI), adjusted for age (categorical: <50, 50-59, 60-69, ≥70 years), sex, BMI (categorical:
<25, 25-29.9, ≥30 kg/m2), gastroesophageal reflux (ever versus no, where available),
education (study specific), smoking exposure (categorical: 0, <15, 15-29, 30-44, ≥45 pack-
years), alcohol intake (categorical: 0, 1-1.9, 2-2.9, ≥3 drinks per day) and study center
(applicable for multicenter studies only). Additional adjustment for antacid use (yes versus
no) had minimal effect on the study-specific and pooled summary estimates so it was not
included in the final model. In all analyses of aspirin and non-aspirin NSAID use, mutual
adjustment for any use of the other type of NSAID was included in each respective model.
This allowed us to observe an effect that accounts for any contribution from the other type
of NSAID. Tests for trends were calculated by modeling exposures as ordinal variables in
multivariate models. In the second stage, we performed a pooled analysis combining study-
specific ORs using a random-effects meta-analytic model to calculate a summary OR. Each
summary OR represents data from only the specific studies that contributed to that exposure
category, thus a study would be excluded from an analysis if it did not generate a stable OR.
Evaluation of heterogeneity and effect modification
The amount of total variation among studies due to heterogeneity was assessed using the I2
statistic 37. Larger I2 values could reflect greater heterogeneity between the study-specific
estimates, beyond what is attributable to chance. We evaluated for potential sources of
heterogeneity using stratified analyses by levels of exposure, gastroesophageal reflux
symptoms, method of evaluating exposure (i.e. type of question) and levels of potential
confounders. To evaluate whether other variables modified the effect of NSAID use on
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cancer risk, we conducted analyses stratified by BMI (<25 kg/ m2, ≥ 25 kg/ m2), smoking
status (never vs. ever), sex, gastroesophageal reflux, age (<60 years, ≥ 60 years), and
education (high school or less, > high school). All analyses were performed using STATA
software, version 10.0 (StataCorp LP, College Station, TX).
Results
The included studies are described in Table 1. The mean age of EAC cases, EGJA cases and
controls was 63.7 years, 63.1 years and 61.7 years, respectively. A large majority of cases
(EAC: 88.4%, EGJA: 85.8%) and controls (68.1%) were male. The overall prevalence of
ever NSAID use among controls was 69%, which varied between studies from 37% to 87%.
Overall, the proportion of persons reporting ever using NSAIDs was 56.6% among EAC
cases and 59.6% among EGJA cases compared to 68.6% among controls.
Overall NSAID use
Compared to non-use, ever use of any NSAID was statistically significantly associated with
a reduced risk of EAC (OR=0.68, 95% CI=0.56-0.82; Table 2; Supplementary Figure 1).
Ever use of NSAIDs was inversely, but not statistically significantly, associated with risk of
EGJA. Furthermore, these associations appeared to be restricted to current users of NSAIDs.
Decreasing risk of EAC was observed with increasing frequency of overall NSAID use.
Occasional use of NSAIDs was associated with an OR of 0.66 (95% CI=0.43-1.00) and
daily or greater use was associated with an OR of 0.56 (95% CI=0.43-0.73; p-trend<0.001).
NSAID use for any duration also appeared to be associated with a reduced risk of EAC, but
a trend of decreasing risk with increased duration was not seen. We found no evidence of a
relationship between increased frequency or duration of NSAID use and risk of EGJA.
Aspirin Use
Five studies collected information on aspirin use. Ever use of aspirin was associated with a
statistically significant 24% decreased risk of EAC (95% CI=3-40%) and a 16% decreased
risk of EGJA (95% CI= 0-31%) compared to non-use (Table 3). The inverse association
with aspirin use and risk of both outcomes appeared to be limited to current use. We
observed a suggestive trend of decreasing risk of EAC associated with increasing frequency
of aspirin use (p-trend=0.03; Supplementary Figure 3), but there was no apparent trend with
increasing duration of aspirin use (p-trend=0.57). Increased frequency or duration of aspirin
use was not statistically significantly associated with risk of EGJA.
Non-aspirin NSAID use
Use of non-aspirin NSAIDs was collected in five BEACON studies. Overall, ever use of
non-aspirin NSAIDS appeared to be statistically significantly associated with a similar
reduced risk of both outcomes compared to non-use: EAC: OR=0.79 (95% CI=0.66-0.95);
and EGJA: OR=0.80 (95% CI=0.67-0.94; Table 4). Although not statistically significant and
based on a small number of cases, this association may be restricted to current users (Table
4). Beyond any use of non-aspirin NSAIDs, we did not observe a clear trend with increasing
frequency or duration of non-aspirin NSAID use with risk of EAC or EGJA.
Type of NSAID use
Among controls who reported using any type of NSAID, 38% reported use of aspirin only,
22% reported use of non-aspirin NSAIDs only, and 41% reported use of both types of
NSAIDs. Compared to those who reported no NSAID use, the use of either aspirin only or
non-aspirin NSAIDs only appeared to be associated with almost identical reduced risks of
EAC (ORs of 0.68 and 0.66), and EGJA (ORs of 0.92 and 0.93), respectively (Table 5).
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Individuals who reported use of both types of NSAIDs were not at significantly reduced risk
of EAC; however, they had a statistically significant reduced risk of EGJA than those who
reported individual use of aspirin or non-aspirin NSAIDs.
We further evaluated the association between ever use of aspirin and other NSAIDs and risk
of each outcome through stratified analyses by other variables: BMI, smoking status, sex,
gastroesophageal reflux, age, education, and NSAID question type. Risk estimates appeared
similar across strata of these potential risk factors (data not shown).
Discussion
We found that users of NSAIDs, in particular those reporting current use, experienced a
statistically significant lower risk of EAC than those who did not use these medications. We
also observed statistically significant inverse associations between greater frequency and
duration of NSAID use and risk of EAC. When the analysis was examined by type of
NSAID, the magnitude of the effect for ever use of aspirin was similar to the effect for ever
use of non-aspirin NSAIDs. However, there was little evidence of a dose-response effect
when examining type of NSAID by increasing frequency or duration. The patterns and
overall inverse association between NSAID and aspirin use and risk of EGJA appear to be
similar to EAC but less striking.
An inverse relationship between NSAID use and esophageal and gastric adenocarcinomas
has been reported previously in reviews and meta-analyses 27-31. An important advantage of
our pooled study is that we were able to create more standardized categories of exposure
using individual-level data from each study and harmonized analytic models with respect to
covariates for adjustment of potential confounding; these steps permit more comparable data
than is possible using only results from published odds ratios, which utilize different sets of
covariates between studies. We also built on past reviews by evaluating additional aspects of
NSAID use, such as frequency, duration, and temporal factors, in a larger number of cases
and controls than previous reports. In the most recently published meta-analysis, Abnet et al.
reported that any aspirin use was inversely associated with EAC and EGJA cancers with
summary ORs of 0.64 (95% CI=0.52-0.79) and 0.82 (95% CI=0.65-1.04), respectively 29.
Both are similar to the estimates we observed from our pooled study. We consistently
observed that the effect of aspirin and NSAID use was slightly weaker for EGJA than EAC.
Although only a few reviews evaluated both EAC and EGJA 29, 30, the summary estimates
reported are consistent with our observations of a stronger association with EAC. This is
also consistent with past meta-analyses that reported a statistically significant reduced risk
for gastric non-cardia cancer with NSAID use but a weaker effect for EGJA 28, 31. Since
these meta-analyses were published, one additional prospective study found an inverse
association between regular use of aspirin and risk of EGJA 26. Four additional studies
conducted among high-risk cohorts of patients with Barrett's esophagus, two prospective and
two retrospective, have also observed evidence of a reduced risk of progression to EAC with
NSAID use 19, 38-40. A pooled analysis of three randomized trials of daily aspirin use and at
least 5 years of treatment found a delayed but significant reduction in deaths due to EAC
and EGJA after 5+ and 10+ years of post-trial follow-up, respectively 41. Although, a small,
short-term trial of celecoxib/placebo among subjects with Barrett's esophagus found no
change in the proportion of dysplastic biopsies between the treatment (200 mg/pill, 2 pills/
day) and placebo group at 48 weeks42, almost half of these patients already had dysplasia at
study entry; a much larger randomized trial, including adequate numbers of patients without
dysplasia, is needed in order to fully explore this hypothesis. A randomized trial of aspirin
and proton pump inhibitors among patients with Barrett's esophagus is currently ongoing in
the United Kingdom 43. Results from this trial will assist in the ongoing effort to further
examine the relationship between aspirin and the development of EAC.
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In our study, the association with ever use of aspirin and non-aspirin NSAIDs was generally
similar for EAC risk. This is in agreement with findings from other reviews that evaluated
the effect of NSAIDs by type. All of our analyses were mutually adjusted for the other type
of NSAID, which did not change any of the observed associations substantially. This
suggests that although similar in effect estimates, both aspirin and non-aspirin NSAID use
appear to have an individual effect on EAC risk above and beyond use of the other type of
NSAID. That is, exposure to any member of this class of medication further reduces the risk
of EAC. The similar effects of aspirin and non-aspirin NSAID use is substantiated further by
the nearly identical associations observed between individuals who reported using aspirin
only and individuals who reported using non-aspirin NSAIDs only with EAC and EGJA
risk. As experimental studies have reported similar pathways and actions of aspirin and
other NSAIDs, such as inhibiting COX-2, decreasing inflammation, increasing apoptosis
and decreasing proliferation, it seems reasonable that there would be little difference
between their effects on EAC or EGJA risk 44, 45.
Frequency of NSAID use appeared to be more strongly associated with a reduction in EAC
risk than duration of NSAID use in this analysis. Our analysis found an inverse relationship
with increased frequency of NSAID use (p-trend<0.001), but a consistent reduced risk of
EAC with any level of duration. A similarly strong inverse dose-response between frequent
NSAID use and esophageal cancer was also reported in the meta-analysis by Corley et al. 27.
None of the previous EAC meta-analyses evaluated the effect of duration of use so we were
unable to compare our results with others. Although we observed an association with risk of
EAC, we found no significant associations among the highest categories of frequent or
longer duration of NSAID use and risk of EGJA. In a meta-analysis by Wang et al., an
inverse association with “regular” or frequent use of NSAIDs and gastric cancer was
observed; however, there was inadequate evidence to suggest an association with duration of
NSAID use in their analysis 28. The interpretation of results on frequent NSAID use from
the Wang et al. meta-analysis, however, is limited due to the inclusion of a mixture of
gastric cancer sites and varying definitions of “regular” NSAID use across studies included
in their meta-analysis.
Although analyses were limited to a subset of studies, in our study it appears that the
reduced risk of EAC and EGJA was restricted to those who reported current use of NSAIDs.
Past reviews have not attempted to summarize the effect of current NSAID status on risk of
either EAC or EGJA. This is most likely due to the lack of published estimates, whereas we
were able to utilize raw data from three of the six BEACON studies to construct this
variable. The current NSAID users in our study tended to report frequent NSAID use
(median = ∼1 pill/day) and a moderate duration of use (median = 5 years). A similar pattern
with current NSAID status has been observed in the one prospective study of Barrett's
esophagus patients. Vaughan et al.19 observed that current NSAID use at baseline was
associated with a significantly lower risk of EAC, which was stronger in a subset of patients
who were deemed to be current users for the full duration of follow-up (median = 5.5 years).
Results from our study could suggest a possible short-term protective effect of NSAIDs on
EAC and EGJA risk as we observed an effect with current users, higher frequency but not
longer duration. However, as our pooled analysis consisted primarily of data from case-
control studies, some of the observed effect could be due to reverse causation. Continued
NSAID use can lead to erosive tissue damage in the gastrointestinal tract, which may result
in patients with gastroesophageal reflux discontinuing NSAID use. However, the study's
supplemental analyses did not support this possibility; a similar effect of aspirin and
NSAIDs use and risk of EAC and EGJA was observed among individuals with or without
gastroesophageal reflux. In addition, findings from the NIH-AARP study, a prospective
cohort included in this analysis, were similar to findings of EGJA risk among case-control
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studies in this analysis. If replicated in further prospective studies and randomized trials, this
could have implications on the use of NSAIDs as a potential preventative measure.
Our pooled study has a number of strengths as well as limitations. It included and combined
data from six population-based case-control and cohort studies. This allowed for a large
sample size and suitable statistical power to evaluate overall main effect associations,
though the case numbers were still small in some strata and limited our power to fully
evaluate effect modification. Combining data from a subset of our studies with extensive
questions on usage also gave us the ability to evaluate characteristics of NSAID use which
has been limited in past reviews. There was some variability among questions from different
studies; in particular, we noticed two general patterns in how questions were asked. When
the lead-in question included the definition of “regular use,” the prevalence of NSAID use
among controls was around 40%; while broader questions reported a prevalence of around
70% among controls (Appendix A). Despite the two patterns of questions, results stratified
by question type demonstrated consistently inverse associations. There were also some
minor differences on how frequency of use was collected: open-ended vs. pre-determined
responses, and what time period served as the reference period for estimating usage
(Appendix A). Assuming the time period was representative of usual usage, we were able to
define NSAID use in the same way across studies. Detailed individual-level data on known
and suspected risk factors for EAC and EGJA were available for pooling from each study,
thus allowing us to control for possible confounding from a standard set of risk factors
across each study. There was some evidence of moderate heterogeneity between study
populations; however, overall, there appears to be little evidence of heterogeneity across the
majority of results except for duration of aspirin. Overall NSAID duration might have been
overestimated, since we were unable to take into account potential concurrent use of aspirin
and non-aspirin NSAIDs in the calculation. However, we re-evaluated overall NSAID
duration taking into account concurrent use in two studies that collected sufficient data to
carry out this analysis, and found that there was very little difference in study-specific
estimates. Another limitation of our data is that no dosage information was collected in any
of the studies. Inclusion of NSAID amounts would have provided a better indicator of drug
exposure than frequency and duration alone. As most participating studies were case-control
studies, data from these studies may be subject to biases; however, data from each study
were obtained rapidly after enrollment and collected with detailed procedures. Results were
also generally similar to those of the cohort study. Finally, we were unable to directly
evaluate whether NSAID use varied by Barrett's esophagus status and whether this would
have had an effect on reported associations, as the number of cases with information on
Barrett's esophagus diagnosis (n=93) was not large enough to conduct any suitably powered
analyses. However, with the small proportion of cancer cases with a prior Barrett's
diagnosis, any effect on the overall results is likely to be small.
In summary, findings from this pooled analysis support the hypothesis that NSAID use
provides potential benefits in preventing esophageal and esophagogastric adenocarcinomas.
There is also evidence to suggest that increased frequency and longer duration of overall
NSAID use is associated with further reduced risk of EAC, but these associations are not
present when evaluated by NSAID type. Results from stratified analyses indicate that aspirin
and non-aspirin NSAIDS have a similar effect on EAC risk overall. While the use of
NSAIDs as a chemopreventive strategy is promising, the effectiveness of NSAIDs still has
to be evaluated in randomized trials before this approach is advanced clinically.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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least 2 times per
week for 1
month or more)





ago, did you take
any of the meds
at least 1/wk, for
6 months or
longer?






used any of the
following meds?







during the past 5
years?
Past 5 yrs at entry Yes, categories
(Occasionally, <1/mo, 2-3x/
mo, 1x/wk, 2-3x/wk, 4-7x/









take any of these
meds regularly
(at least 1/wk for
6 mos or
longer)?








you take any of
the following
meds?
Past 1 yr at entry Yes, categories (<2x/mo,
2-3x/mo, 1-2x/wk, 3-4x/wk,
4-5x/wk, 1x/day, 2 or more
x/day)
No
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